What are the causes, clinical presentation, diagnostic work‑up, and management of salt‑wasting syndromes?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Salt-Wasting Syndromes

Salt-wasting syndromes encompass a spectrum of inherited and acquired disorders characterized by renal sodium loss, hyponatremia, and volume depletion, with Bartter syndrome representing the most well-characterized inherited form requiring immediate sodium chloride supplementation (5-10 mmol/kg/day) plus NSAIDs, while cerebral salt wasting demands aggressive isotonic saline replacement to prevent life-threatening hypovolemia.

Causes

Inherited Salt-Wasting Tubulopathies

Bartter Syndrome is the prototypical genetic salt-wasting disorder, with five distinct subtypes (BS1-5) caused by mutations affecting salt reabsorption in the thick ascending limb of Henle's loop 1:

  • Type 1 (SLC12A1): NKCC2 transporter defect, autosomal recessive
  • Type 2 (KCNJ1): ROMK potassium channel defect, autosomal recessive
  • Type 3 (CLCNKB): ClC-Kb chloride channel defect, autosomal recessive (milder phenotype)
  • Type 4a/4b (BSND, CLCNKA+CLCNKB): Barttin or combined chloride channel defects, autosomal recessive, often with sensorineural deafness
  • Type 5 (MAGED2): MAGE-D2 regulatory protein defect, X-linked recessive (transient)

Gitelman Syndrome affects the distal convoluted tubule and can be clinically indistinguishable from BS3 1.

Endocrine Salt-Wasting Syndromes

Beyond 21-hydroxylase deficiency (congenital adrenal hyperplasia), other endocrine causes include 2:

  • Aldosterone synthase deficiency: Later presentation, less severe biochemistry
  • Pseudohypoaldosteronism type 1: Renal (milder) vs. systemic (severe, earliest presentation with highest sodium requirements)
  • Congenital adrenal hypoplasia: Rare, severe presentation

Acquired Cerebral Salt Wasting (CSW)

CSW occurs in critically ill patients with central nervous system pathology 3, 4:

  • Neurosurgical conditions (subarachnoid hemorrhage, traumatic brain injury, subdural hematoma)
  • Meningitis (including tuberculosis)
  • Status epilepticus
  • Brain tumors (medulloblastoma)
  • Sepsis
  • Ketamine infusion

Clinical Presentation

Bartter Syndrome

Antenatal/Neonatal Features (BS1, BS2, BS4) 1:

  • Polyhydramnios with premature delivery
  • Severe polyuria and dehydration at birth
  • Failure to thrive
  • Growth retardation
  • Hypercalciuria with nephrocalcinosis (except BS3)
  • Sensorineural deafness (BS4a/4b only)

Later Childhood Features (BS3, milder variants):

  • Salt craving
  • Muscle weakness
  • Incidental hypokalemia
  • Preserved urine concentrating ability

Cerebral Salt Wasting

Key Clinical Triad 3, 5:

  • Hyponatremia (often severe, <130 mmol/L)
  • Hypovolemia (critical distinguishing feature from SIADH)
  • Increased urine output (polyuria, often >4 L/day)

Additional features include headache, altered mental status, seizures, and in LVAD patients, low-flow alarms due to preload dependence 6.

Endocrine Salt-Wasting Syndromes

Systemic pseudohypoaldosteronism type 1 presents earliest with the most severe biochemical derangements and highest sodium supplementation requirements at onset, while aldosterone synthase deficiency and renal pseudohypoaldosteronism type 1 present later with overlapping, less severe profiles 2.

Diagnostic Work-Up

Bartter Syndrome

Biochemical Hallmarks 1:

  • Hypokalemia
  • Hypochloremic metabolic alkalosis
  • Normotensive hyperreninemic hyperaldosteronism
  • Elevated urinary sodium and chloride (inappropriate for volume status)
  • Hypercalciuria (BS1, BS2, BS4) vs. normal/low calciuria (BS3)
  • Hypomagnesemia (variable)

Imaging:

  • Renal ultrasound: Medullary nephrocalcinosis (BS1, BS2, BS4)

Genetic Testing: A diagnostic gene panel should include at minimum: SLC12A1, KCNJ1, CLCNKB, BSND, CLCNKA, MAGED2, plus SLC12A3 (Gitelman syndrome) for differential diagnosis 1. Additional genes may be included for broader differential (pseudohypoaldosteronism, Liddle syndrome, apparent mineralocorticoid excess).

Cerebral Salt Wasting vs. SIADH

Critical Distinction - Volume status is the key differentiator 5, 7:

CSW (Hypovolemic):

  • Low jugular venous pressure
  • Orthostatic hypotension
  • Tachycardia
  • Poor skin turgor
  • Elevated BUN/creatinine ratio
  • Elevated hematocrit

SIADH (Euvolemic/Hypervolemic):

  • Normal jugular venous pressure
  • No orthostatic changes
  • Normal BUN/creatinine ratio

Overlapping Laboratory Features (cannot distinguish) 3, 5:

  • Hyponatremia
  • Hypouricemia with high fractional excretion of uric acid
  • Urine osmolality > plasma osmolality
  • Urine sodium often >30 mmol/L
  • Normal renal, adrenal, thyroid function

Supportive Tests:

  • Brain natriuretic peptide (BNP): May be elevated in CSW
  • Uric acid: Typically low in both conditions

Endocrine Salt-Wasting Syndromes

Initial Evaluation 2:

  • Serum sodium, potassium, chloride, bicarbonate
  • Plasma renin activity and aldosterone
  • Cortisol (rule out adrenal insufficiency)
  • Urine sodium and osmolality
  • Genetic testing for definitive diagnosis

Common Pitfall: Systemic pseudohypoaldosteronism type 1 may initially mimic BS2 in the neonatal period, requiring careful clinical and genetic differentiation 1.

Management

Bartter Syndrome

Sodium Chloride Supplementation 1:

  • Dose: 5-10 mmol/kg/day (pharmacologic doses)
  • Spread throughout the day for better tolerance
  • Beyond infancy, spontaneous salt craving may provide partial supplementation
  • Exception: Do NOT supplement in patients with secondary nephrogenic diabetes insipidus (hypernatremic dehydration with urine osmolality < plasma osmolality)

Potassium Chloride Supplementation 1:

  • Use potassium chloride specifically (NOT potassium citrate, which worsens alkalosis)
  • Do NOT aim for complete normalization of potassium (risk of complications)
  • Severe hypokalemia can cause paralysis, rhabdomyolysis, cardiac arrhythmias

NSAIDs 1:

  • Mainstay of treatment, especially in early childhood
  • Inhibit prostaglandin E2 production (pathophysiologically driven by tubuloglomerular feedback)
  • Exception: Avoid in transient BS5
  • Long-term NSAID use carries theoretical risk of chronic kidney disease (data lacking)

Magnesium Supplementation 1:

  • Use organic magnesium salts (better bioavailability)
  • As needed for hypomagnesemia

Alternative Therapies (limited evidence):

  • Potassium-sparing diuretics (amiloride, spironolactone)
  • ACE inhibitors or angiotensin receptor blockers
  • Evidence for efficacy, tolerability, and safety is limited 1

Prenatal Management (if polyhydramnios diagnosed) 1:

  • Maternal NSAIDs carry significant fetal risks (ductus arteriosus constriction, necrotizing enterocolitis, intestinal perforation)
  • Serial amniocentesis is an alternative
  • Requires multidisciplinary team: maternal-fetal medicine, neonatology, pediatric cardiology, pediatric nephrology
  • Fetal echocardiography mandatory if NSAIDs used
  • Formal recommendation cannot be made due to lack of prospective data and publication bias

Cerebral Salt Wasting

Acute Management 5, 7, 6:

Initial Treatment (European unifying protocol):

  • 3% hypertonic saline boluses over 20 minutes via peripheral vein
  • Goal: Increase serum sodium by 5 mEq/L over 1-2 hours
  • This approach is safer when uncertain whether patient has CSW vs. SIADH

Ongoing Management:

  • Isotonic saline infusion: 1:1 volume replacement for urine output
  • Hypertonic saline boluses: Intermittent as needed
  • Fludrocortisone: Daily mineralocorticoid supplementation
  • Desmopressin: Low-dose to reduce polyuria
  • Salt tablets: Maintain serum sodium 135-140 mmol/L
  • Goal urine output: 2.5-3.5 L/day

Critical Consideration: In LVAD patients, CSW causes preload-dependent low-flow alarms requiring aggressive volume replacement 6. Failure to rapidly treat can lead to respiratory arrest, brainstem herniation, and death.

Treatment Duration: Mean time to correction of hyponatremia is approximately 20 days 4.

Endocrine Salt-Wasting Syndromes

General Principles 2:

  • Sodium supplementation requirements vary by etiology (highest in systemic pseudohypoaldosteronism type 1)
  • Mineralocorticoid therapy (fludrocortisone) for aldosterone deficiency states
  • Time to electrolyte stabilization does not differ significantly across etiologies
  • Growth outcomes are generally preserved with appropriate management
  • Systemic pseudohypoaldosteronism type 1 shows greater auxological vulnerability

Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency)

Newborn Screening 8:

  • All newborns should be screened using two-tier protocol (initial immunoassay, confirmatory liquid chromatography/tandem mass spectrometry)
  • Reduces morbidity and mortality from salt-wasting crises
  • Particularly benefits males (no genital ambiguity to alert clinicians)
  • Death rate without screening: 4-10%
  • Screening reduces mean serum sodium at diagnosis (134 mM vs. 124 mM without screening)

Common Pitfalls

  1. Misdiagnosing CSW as SIADH: Always assess volume status clinically; laboratory values alone cannot distinguish these conditions. Treating CSW with fluid restriction (SIADH management) can be fatal 5, 7.

  2. Using potassium citrate instead of potassium chloride in Bartter syndrome: This worsens metabolic alkalosis 1.

  3. Aggressive sodium supplementation in Bartter syndrome with nephrogenic diabetes insipidus: This worsens polyuria and risks hypernatremic dehydration 1.

  4. Overlooking CSW in non-neurosurgical patients: Increasingly recognized in sepsis, status epilepticus, and drug-induced cases 4.

  5. Prenatal NSAID therapy without multidisciplinary oversight: High risk of fetal ductus arteriosus constriction and necrotizing enterocolitis 1.

  6. Confusing systemic vs. renal pseudohypoaldosteronism type 1: Systemic form presents earlier with more severe biochemistry and higher treatment requirements 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.